Nautilus Biotechnology, Inc. cotiza a 2.05 USD y tiene una capitalización bursátil de $261M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, co…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.11 | $-0.12 | $-0.11 |
| Estimado | $-0.16 | $-0.14 | $-0.14 | $-0.14 |
| Sorpresa | — | +21.4% | +14.3% | +21.4% |
| Métrica | NAUT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -37.6% | -40.4% | +2.8% |
| ROA | -30.9% | -32.0% | +1.1% |
| Current Ratio | 13.33 | 2.84 | +10.49 |
| Debt / Equity | — | 0.28 | — |